Stress affects everyone. It can be due to work, family, health, or just the fast pace of modern life. No matter what the reason, stress often leaves you feeling tired, anxious, and mentally ...

Followed categories will be added to My News. We are designed to cope with stress very effectively in the short term. However, we have not evolved to cope with stress in the long term without a ...

Stress related to money is pervasive, but there are ways to handle it. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain ...

World Hypertension Day, observed on May 17th, raises awareness about high blood pressure and its consequences. Managing hypertension involves lifestyle changes like the DASH diet, which emphasizes ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

About 12M long COVID patients have reported 'brain fog' New study examined 17 people, including 10 with neurological symptoms Findings validate the experiences of 'long-haulers' About 12M long ...

A global survey of 30,000 pet owners found that 65 percent of people would prefer to de-stress in the company of their dog, cat or other household pet – significantly more than those who said ...

Presently, there are many younger artists. One I am constantly reminded of is Igan D’Bayan as one of his “Headshot” series, oil on canvas, hangs right beside the main door of my son Vernon ...

BATON ROUGE, La. (WAFB) - Nick Laborde’s head was spinning on his most recent trip to the New Orleans airport. And it’s because his Real-ID wasn’t really working. ”They ran my ID and put it in the ...

JADE101: potentially best-in-class anti-APRIL monoclonal antibody for IgAN First-in-human clinical trial anticipated to begin in the second half of 2025 with interim data expected in the first half of ...